Peloton Therapeutics is translating groundbreaking scientific insights into first-in-class oral medicines to fight cancer and other serious conditions.
Total raised: $40.2M
Investors 4
| Date | Name | Website |
| 13.04.2024 | Vida Ventu... | vidaventur... |
| - | Curative V... | curativeve... |
| - | RA Capital... | racap.com |
| - | The Column... | thecolumng... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.03.2017 | Series D | $22.2M | - |
| 27.07.2011 | Series A | $18M | - |
Mentions in press and media 13
| Date | Title | Description |
| 21.05.2019 | Term Sheet — Tuesday, May 21 | DEBUT DEAL Mary Meeker has made her first investment out of Bond Capital, the new firm she launched after spinning out of Kleiner Perkins last year. Paid Content You can't secure what you can't see From ExtraHop The funding announcement mad... |
| 20.02.2019 | Peloton Therapeutics Secures $150 Million in Series E Financing | - |
| 20.02.2019 | Peloton Therapeutics Secures $150 Million in Series E Financing | - |
| 21.03.2017 | Peloton Therapeutics Snags $22.2M | DALLAS, TX, Peloton Therapeutics raised $22.2 million in additional Series D funding, closing the round at $74.6 million. >> Click here for more funding data on Peloton Therapeutics >> To export Peloton Therapeutics funding ... |
| 16.03.2017 | Term Sheet — Thursday, March 16 | THE CRAFT BEER BATTLE MOVES TO CHINA Good morning, Term Sheet readers. Today’s column (tipple?) is from Fortune editor Matt Heimer. Enjoy. Paid Content What you need to know about growing cyberattacks From ExtraHop In the wider beer world, ... |
| 15.03.2017 | Peloton Therapeutics Raises $22.2M | DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies, announced today the exercise of an optional tranche of its previously-announ... |
| 14.03.2017 | Pushing ahead with cancer drug research, Peloton brings its latest round to $75M | Steven L. McKnight Dallas-based Peloton Therapeutics has bagged an extra $22.2 million for its Series D round, bringing the total to $74.6 million. Much of that money is being earmarked for PT2385, an early-stage drug which ... |
| 14.03.2017 | Peloton Therapeutics Raises $22.2M in Series D Funding | Peloton Therapeutics, Inc., a Dallas, TX-based drug discovery and development company, raised an additional $22.2m in Series D funding. This adds to the earlier Series D close of $52.4m, bringing the full amount raised in the Series D finan... |
| 15.09.2016 | Peloton Therapeutics Lands $52.4M Financing | DALLAS, TX, Peloton Therapeutics, a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies, announced today the completion of a $52.4 million Series D financing round. >> Click h... |
| 27.07.2011 | Peloton Therapeutics Completes $18M Series A Financing | Peloton Therapeutics, Inc., a Dallas-based early-stage cancer drug discovery and development company, completed an $18m Series A financing. The round was led by The Column Group, with participation from Remeditex Ventures and Peter O’Donnel... |
Show more